
TLSA Stock Forecast & Price Target
TLSA Analyst Ratings
Bulls say
Tiziana Life Sciences is supported by a compelling, mechanism-driven thesis centered on intranasal foralumab, which has repeatedly shown TSPO-PET reductions, Treg stimulation, and lower CNS inflammation across SPMS, MSA, and AD. The near-term catalyst is the 48-patient INFORM-MS Phase 2a readout expected in October 2026, with the last patient completing the last visit on 9/21/26, and a meaningful signal could de-risk the broader pipeline, especially given reported stability or improvement in all 14 Expanded Access Program patients within 6 months. Its attractiveness is further reinforced by no serious adverse events across 37 patient years of exposure, orphan-like unmet need in SPMS and MSA, and a broad patent estate that extends core foralumab protection to 2037 with additional families potentially lasting into 2042 to 2046.
Bears say
Tiziana Life Sciences is viewed negatively because its clinical-stage pipeline faces unusually high scientific and regulatory risk: neuroscience is complex, drug discovery is inherently risky, and the FDA may demand larger, well-controlled datasets and possibly two trials for full approval in SPMS, MSA, and AD. As a small biopharmaceutical company with no approved products and a limited operating history, it has incurred significant operating losses since inception and will likely need substantial additional capital, with financing constraints risking delays or scaled-back development. Foralumab also faces mechanistic uncertainty, potential weaker efficacy in later-stage patients, intensifying competition in neuroinflammation, and third-party dependency risk because patent prosecution for licensed technology is controlled by NovImmune and Brigham and Women’s Hospital.
This aggregate rating is based on analysts' research of Tiziana Life Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLSA Analyst Forecast & Price Prediction
Start investing in TLSA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tiziana Life Sciences Ltd (TLSA) Forecast
TLSA Analyst Forecast & Price Prediction
Start investing in TLSA
Order type
Buy in
Order amount
Est. shares
0 shares